Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines
- PMID: 8208536
Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines
Abstract
Cells with divergent mutant alleles of the p53 gene have different biological and biochemical properties in vitro. Increasing evidence indicates that p53 is a transcriptional activator, and recently, high affinity DNA binding sites for p53 have been identified. The purpose of this study was to determine in vivo, the effect that various mutant p53 proteins have on their ability to mediate transactivation and to bind specifically to DNA. Either a p53 responsive or control reporter gene was transfected into 18 human carcinoma cell lines, having various p53 mutations, either with or without a wild-type p53 expression vector. The CAT activity and DNA gel retardation were studied to measure transactivation and DNA binding by these endogenous p53s. As expected, the endogenously produced wild-type p53 binds to DNA binding sequences and can transactivate a reporter construct containing a p53 high affinity DNA binding site. Four of five cell lines with homozygous p53 mutations at codon 273 (273His), contained p53 which had the ability to bind to p53 DNA binding sequences and transactivate. In contrast, all the homozygous, non-codon 273 mutant p53s (156Pro, 175His, 223Leu, 248Gln, 248Trp, 280Lys) present in the other cell lines had no transactivating ability. These findings suggest that the biology of cancers with mutations at codon 273 may be different than those with p53 mutations at other sites. The p53 from WRO, a thyroid carcinoma cell line with p53 mutation at codon 223 (223Leu), was able to bind p53 DNA recognition sequences, but was unable to transactivate. Interestingly, in a vulvar carcinoma cell line (A431) with a p53 mutation at codon 273 (273His), the p53 was unable to transactivate and gave an aberrant band on gel retardation. Both CEM and SK-UT-1, which have compound heterozygous mutations at codons 175/248 (175His/248His), produced p53 which can complex with DNA, as well as transactivate. In contrast, the p53 in cell lines with either homozygous 175His or 248His p53 mutations, were unable either to transactivate or bind to the p53 response element. A cell line (NPA) heterozygous for 266Glu p53 mutation, was able to efficiently transactivate a reporter containing a p53 DNA binding site, therefore showing no evidence of a dominant negative effect of the endogenous p53 mutant allele. In summary, this in vivo study further supports the idea that different p53 mutant alleles have various properties which may affect their function.
Similar articles
-
p53 transactivation through various p53-responsive elements.Mol Carcinog. 1996 Jun;16(2):101-8. doi: 10.1002/(SICI)1098-2744(199606)16:2<101::AID-MC6>3.0.CO;2-L. Mol Carcinog. 1996. PMID: 8645424
-
Mutant p53 proteins behave in a dominant, negative fashion in vivo.Anticancer Res. 1994 Sep-Oct;14(5A):1853-9. Anticancer Res. 1994. PMID: 7847818
-
Analysis of p53 transactivation through high-affinity binding sites.Oncogene. 1993 Nov;8(11):3005-11. Oncogene. 1993. PMID: 8414502
-
[Dominant negative activity of mutated p53 proteins].Med Sci (Paris). 2006 Mar;22(3):301-7. doi: 10.1051/medsci/2006223301. Med Sci (Paris). 2006. PMID: 16527213 Review. French.
-
Biochemical properties of the growth suppressor/oncoprotein p53.Oncogene. 1992 Sep;7(9):1673-80. Oncogene. 1992. PMID: 1501881 Review.
Cited by
-
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.J Clin Invest. 2011 Mar;121(3):893-904. doi: 10.1172/JCI44504. J Clin Invest. 2011. PMID: 21285512 Free PMC article.
-
An incoherent feedforward loop facilitates adaptive tuning of gene expression.Elife. 2018 Apr 5;7:e32323. doi: 10.7554/eLife.32323. Elife. 2018. PMID: 29620523 Free PMC article.
-
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.Nat Commun. 2020 Apr 29;11(1):2086. doi: 10.1038/s41467-020-15608-y. Nat Commun. 2020. PMID: 32350249 Free PMC article.
-
The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.BMC Cancer. 2020 Aug 8;20(1):738. doi: 10.1186/s12885-020-07212-6. BMC Cancer. 2020. PMID: 32770960 Free PMC article.
-
Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53.Br J Cancer. 2008 Apr 22;98(8):1431-3. doi: 10.1038/sj.bjc.6604258. Epub 2008 Mar 18. Br J Cancer. 2008. PMID: 18349850 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous